Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H(1)-antihistamines |
| |
Authors: | Maurer Marcus Church Martin K |
| |
Institution: | Department of Dermatology and Allergy, Allergie‐Centrum‐Charité, Charité– Universit?tsmedizin Berlin, Berlin, Germany |
| |
Abstract: | Icatibant, a bradykinin-2 receptor antagonist, is administered by subcutaneous injection for the treatment of attacks of type I and type II hereditary angioedema. Following injection, patients feel transient pain followed by a short-lived wheal and flare response at the injection site. We hypothesized that the icatibant-induced wheal and flare response follows histamine release from activated skin mast cells and would therefore be reduced by an H(1)-antihistamine. Intradermal injection of 100 μl of 100 μg/ml histamine and 10 mg/ml icatibant into the forearms of health volunteers caused wheal and flare responses of a similar magnitude which were reduced by cetirizine pretreatment by 49% and 41% (histamine) and 35% and 41% (icatibant). Studies in vitro showed that icatibant at 1 × 10(-4) and 1 × 10(-5) M caused significant (P < 0.05) histamine release from isolated human cutaneous mast cells. In conclusion, icatibant induces histamine-mediated wheal and flare responses that may be reduced in severity by prophylactic administration of an H(1)-antihistamine. |
| |
Keywords: | cetirizine H1‐antihistamine icatibant –mast cell wheal and flare |
本文献已被 PubMed 等数据库收录! |
|